Preventable liver disease costs more than diabetes: Team hopes to reduce burden with research-led intervention

Liver diseases have an impact on the Australian economy 40 per cent greater than chronic kidney disease and Type 2 diabetes combined, according to a report released today.

The report estimates the annual burden of liver diseases in Australia at more than $50 billion. And yet almost all liver disease is preventable.

The Centenary Institute's liver research unit is one of the biggest in Australia. It is also one of first in the world to try to come to grips with liver damage at its most fundamental molecular level.

Head of research into liver disease and damage at Centenary, Professor Geoff McCaughan, and his team are focusing their research on promoting liver health, and understanding how chronic liver damage can develop into .

"New therapies against together with public health measures in the fields of alcohol abuse and obesity would be a start in the fight to reduce the burden of liver disease," says Prof McCaughan. "We are exploring ways to detect early liver cancer and to understand how liver cancers are resistant to therapies."

can be caused by viral infections such as Hepatitis B and C, as well as autoimmune diseases and lifestyle-related illnesses such as alcoholism, diabetes and obesity.

"We're working on important projects exploring new therapeutic targets which could potentially lead to new therapies across a broad spectrum of ," says Prof McCaughan.

And by working with the Royal Prince Alfred Hospital (RPA), Centenary's advances in research can be put into practice in the clinic in the minimum time possible.

The research group has received a $2.5-million grant from the US National Institutes of Health to test the genes of hundreds of Sydney-siders to work out why some heavy drinkers develop and some don't.

They have also demonstrated the effectiveness of new Hepatitis C treatments which, when used in conjunction with existing therapy, boost the percentage of patients who clear the virus from 45 per cent to 70 per cent.

Prof McCaughan is the chair of the Australian Liver Association, which commissioned the report, and Director of the Australian Liver Transplant Unit at RPA. He believes the report is long overdue.

"It shows categorically that any advance in treating or preventing liver disease would not only benefit patients, but also the country's bottom line."

"Supporting the report's recommendations, which include more complete collection of data, trials of hospital and community treatment programs, and screening for the more serious forms of , makes both human and economic sense," says Prof McCaughan.

More information: A copy of the report and further information at: www.gesa.org.au

add to favorites email to friend print save as pdf

Related Stories

How liver kills 'killer cells'

Sep 19, 2011

Our livers can fight back against the immune system -- reducing organ rejection but also making us more susceptible to liver disease.

Recommended for you

Recorded Ebola deaths top 7,000

8 hours ago

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

12 hours ago

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

Dec 19, 2014

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

Dec 19, 2014

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.